Nplate

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
17-10-2022
Karakteristik produk Karakteristik produk (SPC)
17-10-2022

Bahan aktif:

romiplostim

Tersedia dari:

Amgen Europe B.V.

Kode ATC:

B02BX04

INN (Nama Internasional):

romiplostim

Kelompok Terapi:

Antihemorrhagics

Area terapi:

Purpura, Thrombocytopenic, Idiopathic

Indikasi Terapi:

Adults:Nplate is indicated for the treatment of primary immune thrombocytopenia  (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).Paediatrics:Nplate is indicated for the treatment of chronic primary immune thrombocytopenia (ITP) in paediatric patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

Ringkasan produk:

Revision: 26

Status otorisasi:

Authorised

Tanggal Otorisasi:

2009-02-04

Selebaran informasi

                                77
B. PACKAGE LEAFLET
78
PACKAGE LEAFLET: INFORMATION FOR THE USER
NPLATE 125 MICROGRAMS POWDER FOR SOLUTION FOR INJECTION
NPLATE 250 MICROGRAMS POWDER FOR SOLUTION FOR INJECTION
NPLATE 500 MICROGRAMS POWDER FOR SOLUTION FOR INJECTION
Romiplostim
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Nplate is and what it is used for
2.
What you need to know before you use Nplate
3.
How to use Nplate
4.
Possible side effects
5.
How to store Nplate
6.
Contents of the pack and other information
1.
WHAT NPLATE IS AND WHAT IT IS USED FOR
Nplate’s active ingredient is romiplostim, which is a protein used
to treat low platelet counts in
patients with immune primary thrombocytopenia (called ITP). ITP is a
disease in which your body’s
immune system destroys its own platelets. Platelets are the cells in
your blood that help seal cuts and
form blood clots. Very low platelet counts can cause bruising and
serious bleeding.
Nplate is used to treat adult patients with ITP who may or may not
have had their spleen removed and
who have been previously treated with corticosteroids or
immunoglobulins, where these treatments
don’t work. Nplate is also used to treat children aged 1 year and
over with chronic ITP who may or
may not have had their spleen removed and who have been previously
treated with corticosteroids or
immunoglobulins, where these treatments don’t work.
Nplate works by stimulating the bone marrow (part of the bone which
makes blood cells) to produce
more platelets. This should help to
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Nplate 125 micrograms powder for solution for injection
Nplate 250 micrograms powder for solution for injection
Nplate 500 micrograms powder for solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Nplate 125 micrograms powder for solution for injection
Each vial contains 125 mcg of romiplostim. After reconstitution, a
deliverable volume of 0.25 mL
solution contains 125 mcg of romiplostim (500 mcg/mL). An additional
overfill is included in each
vial to ensure that 125 mcg of romiplostim can be delivered.
Nplate 250 micrograms powder for solution for injection
Each vial contains 250 mcg of romiplostim. After reconstitution, a
deliverable volume of 0.5 mL
solution contains 250 mcg of romiplostim (500 mcg/mL). An additional
overfill is included in each
vial to ensure that 250 mcg of romiplostim can be delivered.
Nplate 500 micrograms powder for solution for injection
Each vial contains 500 mcg of romiplostim. After reconstitution, a
deliverable volume of 1 mL
solution contains 500 mcg of romiplostim (500 mcg/mL). An additional
overfill is included in each
vial to ensure that 500 mcg of romiplostim can be delivered.
Romiplostim is produced by recombinant DNA technology in _Escherichia
coli_ (_E. coli_).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder for solution for injection (powder for injection).
The powder is white.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Adults:
Nplate is indicated for the treatment of primary immune
thrombocytopenia (ITP) in adult patients who
are refractory to other treatments (e.g. corticosteroids,
immunoglobulins) (see sections 4.2 and 5.1).
Paediatrics:
Nplate is indicated for the treatment of chronic primary immune
thrombocytopenia (ITP) in paediatric
patients one year of age and older who are refractory to other
treatments (e.g. corticosteroids,
immunoglobulins) (see sections 4.2 and 5.1).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Treatment should rema
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 17-10-2022
Karakteristik produk Karakteristik produk Bulgar 17-10-2022
Laporan Penilaian publik Laporan Penilaian publik Bulgar 01-06-2018
Selebaran informasi Selebaran informasi Spanyol 17-10-2022
Karakteristik produk Karakteristik produk Spanyol 17-10-2022
Laporan Penilaian publik Laporan Penilaian publik Spanyol 01-06-2018
Selebaran informasi Selebaran informasi Cheska 17-10-2022
Karakteristik produk Karakteristik produk Cheska 17-10-2022
Laporan Penilaian publik Laporan Penilaian publik Cheska 01-06-2018
Selebaran informasi Selebaran informasi Dansk 17-10-2022
Karakteristik produk Karakteristik produk Dansk 17-10-2022
Laporan Penilaian publik Laporan Penilaian publik Dansk 01-06-2018
Selebaran informasi Selebaran informasi Jerman 17-10-2022
Karakteristik produk Karakteristik produk Jerman 17-10-2022
Laporan Penilaian publik Laporan Penilaian publik Jerman 01-06-2018
Selebaran informasi Selebaran informasi Esti 17-10-2022
Karakteristik produk Karakteristik produk Esti 17-10-2022
Laporan Penilaian publik Laporan Penilaian publik Esti 01-06-2018
Selebaran informasi Selebaran informasi Yunani 17-10-2022
Karakteristik produk Karakteristik produk Yunani 17-10-2022
Laporan Penilaian publik Laporan Penilaian publik Yunani 01-06-2018
Selebaran informasi Selebaran informasi Prancis 17-10-2022
Karakteristik produk Karakteristik produk Prancis 17-10-2022
Laporan Penilaian publik Laporan Penilaian publik Prancis 01-06-2018
Selebaran informasi Selebaran informasi Italia 17-10-2022
Karakteristik produk Karakteristik produk Italia 17-10-2022
Laporan Penilaian publik Laporan Penilaian publik Italia 01-06-2018
Selebaran informasi Selebaran informasi Latvi 17-10-2022
Karakteristik produk Karakteristik produk Latvi 17-10-2022
Laporan Penilaian publik Laporan Penilaian publik Latvi 01-06-2018
Selebaran informasi Selebaran informasi Lituavi 17-10-2022
Karakteristik produk Karakteristik produk Lituavi 17-10-2022
Laporan Penilaian publik Laporan Penilaian publik Lituavi 01-06-2018
Selebaran informasi Selebaran informasi Hungaria 17-10-2022
Karakteristik produk Karakteristik produk Hungaria 17-10-2022
Laporan Penilaian publik Laporan Penilaian publik Hungaria 01-06-2018
Selebaran informasi Selebaran informasi Malta 17-10-2022
Karakteristik produk Karakteristik produk Malta 17-10-2022
Laporan Penilaian publik Laporan Penilaian publik Malta 01-06-2018
Selebaran informasi Selebaran informasi Belanda 17-10-2022
Karakteristik produk Karakteristik produk Belanda 17-10-2022
Laporan Penilaian publik Laporan Penilaian publik Belanda 01-06-2018
Selebaran informasi Selebaran informasi Polski 17-10-2022
Karakteristik produk Karakteristik produk Polski 17-10-2022
Laporan Penilaian publik Laporan Penilaian publik Polski 01-06-2018
Selebaran informasi Selebaran informasi Portugis 17-10-2022
Karakteristik produk Karakteristik produk Portugis 17-10-2022
Laporan Penilaian publik Laporan Penilaian publik Portugis 01-06-2018
Selebaran informasi Selebaran informasi Rumania 17-10-2022
Karakteristik produk Karakteristik produk Rumania 17-10-2022
Laporan Penilaian publik Laporan Penilaian publik Rumania 01-06-2018
Selebaran informasi Selebaran informasi Slovak 17-10-2022
Karakteristik produk Karakteristik produk Slovak 17-10-2022
Laporan Penilaian publik Laporan Penilaian publik Slovak 01-06-2018
Selebaran informasi Selebaran informasi Sloven 17-10-2022
Karakteristik produk Karakteristik produk Sloven 17-10-2022
Laporan Penilaian publik Laporan Penilaian publik Sloven 01-06-2018
Selebaran informasi Selebaran informasi Suomi 17-10-2022
Karakteristik produk Karakteristik produk Suomi 17-10-2022
Laporan Penilaian publik Laporan Penilaian publik Suomi 01-06-2018
Selebaran informasi Selebaran informasi Swedia 17-10-2022
Karakteristik produk Karakteristik produk Swedia 17-10-2022
Laporan Penilaian publik Laporan Penilaian publik Swedia 01-06-2018
Selebaran informasi Selebaran informasi Norwegia 17-10-2022
Karakteristik produk Karakteristik produk Norwegia 17-10-2022
Selebaran informasi Selebaran informasi Islandia 17-10-2022
Karakteristik produk Karakteristik produk Islandia 17-10-2022
Selebaran informasi Selebaran informasi Kroasia 17-10-2022
Karakteristik produk Karakteristik produk Kroasia 17-10-2022
Laporan Penilaian publik Laporan Penilaian publik Kroasia 01-06-2018

Peringatan pencarian terkait dengan produk ini

Lihat riwayat dokumen